ArticleScientific reports2025
Comparative effects of standardized Centella asiatica extract (ECa 233) and its active compound mixture on proteomics and mitochondrial function.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting oxidative stress, senescence, and neurodegeneration: anti-aging perspectives of Urtica dioica and Centella asiatica.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
ECa 233 is a standardized extract of Centella asiatica that contains the major active compounds madecassoside (MDS) and asiaticoside (ASS), which can strengthen hippocampal synapses, resulting in a memory-enhancing effect. This study explored the possible mechanisms of ECa 233 related to synaptic enhancement via proteomic analysis. Differentiated SH-SY5Y cells and hippocampal slices obtained from healthy male Wistar rats were treated with dimethyl sulfoxide, ECa 233, or the MDS + ASS mixture. Mitochondrial function and protein expression were examined via proteomic, western blot, and immunofluorescence analyses. Effects on synaptic plasticity were confirmed via electrophysiology using acute hippocampal slices. The treated groups exhibited a significant increase in mitochondrial activity and synaptic plasticity-related protein expression. Upstream Akt-mTOR signaling was significantly enhanced, with the most pronounced effects observed in the MDS + ASS group. However, the ECa 233 group still showed the highest hippocampal synaptic response. Based on our data, both ECa 233 and MDS + ASS were involved in mitochondrial metabolism, with the Akt-mTOR pathway as one of the targets promoting these activities. Furthermore, the synergistic effect of MDS + ASS was essential to achieve the same level of response obtained with ECa 233. Ultimately, the MDS + ASS mixture may enhance cellular plasticity, while the remaining components of ECa 233 may promote specific proteins that play a role in maintaining biological homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.